Mehmet Özgür Pinarbasli, Ercan Kaya, Evrim Yilmaz, Mehmet Akif Abakay, Melek Kezban Gurbuz, Erkan Niyazi Ozudogru, Funda Canaz

Larenks Kanserinde Fascin-1 ve Galectin-3’ü n Prognostik Önemi

Bu çalışmada birer aktin proteini olan fascin-1 ve galektin-3’ün larenks kanserinin prognozu ile ilişkilerinin değerlendirilmesi amaçlanmıştır. İleri evre laringeal skuamöz hücreli karsinom tanısı alan ve cerrahi olarak tedavi edilen 58 hastaya ait bilgi ve belgeler retrospektif olarak incelendi ve çalışmaya dahil edildi. Cerrahi spesmene ait patoloji preperatları Ventana Universal DAB tespit kiti ile Benchmark boyama platformunda immünohistokimyasal olarak boyandı. Her bir işaretleyici için ışık mikroskobunda en az 1000 hücre sayıldı. Galektin-3 için; % 5’in üzerinde boyanma pozitif,% 5 ve altı boyanma negatif olarak kabul edildi. Fascin-1 için; boyanma yoğunluğu 4 grupta kategorize edildi; 0: boyannma yok; 1: zayıf boyama; 2: orta derecede boyanma; 3: güçlü boyanma ve pozitif hücrelerin yüzdesi 1 ile 4 arasında gruplandı; 1: ≤% 10; 2:% 10-50; 3:% 50-75; 4: ≥75. Ardından elde edilen iki puan toplandı ve 4 ve daha düşük nihai puan düşük boyanma olarak; 5 ve üzeri yüksek boyanma olarak kabul edildi. Fascin-1 ekspresyonu 41 (% 70.68) hastada yüksek bulundu; galektin-3 ekspresyonu 36 (% 62.06) hastada pozitif bulundu. Fascin-1 ve galektin-3, geleneksel prognostik faktörler, hastalıksız hayatta kalma ve hastalıkla ilişkili ölüm ile istatsitiksel olarak hiçbir korelasyon göstermedi. Larenks kanserinde fascin-1 ve galektin-3’ün prognostik değeri bu çalışmada gösterilememiştir. Ancak bugüne kadar herhangi bir larenks kanseri çalışmasında bu iki belirteç birlikte çalışılmadığı için bu çalışma literatüre bu açıdan katkı sağlayabilir. Bu nedenle bu konuda daha fazla çalışmaya ihtiyaç vardır.

The Prognostic Value of Fascin 1 and Galectin 3 in Laryngeal Carcinoma

The aim of this study was to evaluate the prognostic relevance of fascin-1 and galectin-3 that are actin proteins in laryngeal cancer.Informatios and documents of 58 patients diagnosed with advanced laryngeal squamous cell carcinoma and treated surgicallywere included in the study. Surgical specimen slides were stained immunohistochemically at Benchmark staining platform byVentana Universal DAB detection kit. For each marker, least 1000 cells were counted at light microscope. For galectin-3; more than5% staining was considered as positive, %5 and less was accepted as negative. For fascin-1; staining intensity was categorized in 4groups; 0: no staining; 1: weak staining; 2: moderate staining; 3: strong staining,and the percentage of positive cells was groupedfrom 1 to 4 as follows; 1: ≤ 10 %; 2:10-50 %; 3: 50-75 %; 4: ≥75. Then, two scores gathered and final score 4 and less accepted as lowstaining; 5 and more accepted as high staining. Fascin-1 expression was found high in 41(70.68 %); and galectin-3 expression wasfound positive in 36 (62.06 %) patients. Fascin-1 and galectin-3 expressions showed no correlation with conventional prognosticfactors, disease free survival and disease related death, statistically. Prognostic value of fascin-1 and galectin-3 in laryngeal cancercould not be demonstrated in this study. However, this study may contribute to the literature in this respect, as these two markershave not been studied together in any study of laryngeal cancer until now. Therefore, more studies are needed on this subject.

PDF

___

1. Gorphe P, Matias M, Moya-Plana A et al. Results and Survival of Locally Advanced AJCC 7th Edition T4a Laryngeal Squamous Cell Carcinoma Treated with Primary Total Laryngectomy and Postoperative Radiotherapy. Ann Surg Oncol. 2016; 23:2596-601.
2. Sheahan P. Management of Advanced Laryngeal Cancer. Rambam Maimonides Med J. 2014; 5: e0015.
3. Nguyen-Tan PF, Le QT, Quivey JM et al. Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. Int J Radiat Oncol Biol Phys. 2001; 50:1172– 80.
4. Lassaletta L, Garcia-Pallares M, Morera E et al. T3 glottic cancer: oncologic results and prognostic factors. Otolaryngol Head Neck Surg. 2001; 124:556-60.
5. Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2007; 133: 1270–6.
6. Piantelli M, Iacobelli S, Almadori G et al. Lack of expression of Galectin-3ıs associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol. 2002; 20:3850-6.
7. Adams CJ. Fascin protrusions in cell interactions. Trends Cardiovasc Med. 2004; 14:221-6.
8. Zanet J, Jayo A, Plaza S et al. Fascin promotes filopodia formation independent of its role in actin bundling. J Cell Biol. 2012; 197:477-86.
9. Choufani G, Nagy N, Saussez S et al. The levels of expression of galectin-1, galectin-3, and the ThomsenFriedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer. 1999;86: 2353-63.
10. Koo JS1, Jung W. Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J. 2011; 52:89-97.
11. Plzák J, Betka J, Smetana K Jr et al. Galectin-3 an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer. 2004; 15:2324–30.
12. Gao W, Zhang C, Feng Y et al. Fascin-1, Ezrin and Paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma. Plos One. 2012; 7:1-13: e50710. 44
13. Choi JY, Cho SI, Do NY et al. Clinical significance of the expression of galectin-3 and Pim-1 in laryngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg. 2010; 39:28-34.
14. Durmaz A, Kurt B, Ongoru O et al. Significance of fascin expression in laryngeal squamous cell carcinoma. J Laryngol Otol. 2010; 124:194–8.
15. Wu D, Chen L, Liao W et al. Fascin1 expression predicts poor prognosis in patients with nasopharyngeal carcinoma and correlates with tumor invasion. Ann Oncol. 2010; 21:589-96.
16. Zou J, Yang H, Chen F et al. Prognostic significance of Fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. Eur J Cancer Prev. 2010; 19:11–17.
17. Miranda FA, Hassumi MK, Guimarães MC et al. Galectin-3 overexpression in ınvasive laryngeal carcinoma, assessed by computer assisted analysis. J Histochem Cytochem. 2009; 57:665–73.
18. Betka J, Plzák J, Smetana K Jr et al. Galectin-3, an endogenous lectin, as a tool for monitoring cell differentiation in head and neck carcinomas with implications for galectin-glycan functionality. Acta Otolaryngol. 2003; 123:261-3.